While there is no doubt that Type 1 diabetes has affected millions of people around the world, a recent report confirmed that Danish drug company Novo Nordisk is making efforts in the direction of developing a cure for the disease.
On the same lines, the company under the supervision of Dr. Matthias von Herrath, Director of the nonprofit Center for Type 1 Diabetes Research in La Jolla, California, would start a research centre in Novo Nordisk's facilities in South Lake Union next month.
While there are already 70 people employed for the same, there are chances that there would be some 10 to 12 researchers hired for the same centre so that efforts could be stepped up. There is need that efforts are being consistently made in the direction of finding some sort of cure for the disease which makes the body's immune system to attack cells in the pancreas, which are responsible for producing insulin. The most not worthy point with this disease is that it has nothing to do with one’s sedentary lifestyle or eating habits.
While plans of Novo Nordisk all set to expand in Seattle, it has certainly set an example for others to come forward and follow steps which can actually bring some sort of hope for those who are lingering with the disease.
A new study by Toronto researchers on a new way to treat type 2 diabetes shows it may cause temporary remission of the disease in up to 75 per cent of patients.
The new treatment involves taking four shots of insulin -- the medication required by some diabetics to control blood sugar levels -- per day for just one month. This is a change from the usual treatment, which involves daily insulin shots over an extended period of time.
Patients develop diabetes when their pancreas can't produce enough insulin to lower blood sugar levels after meals. While medications can temporarily boost insulin production, many type 2 diabetics face a lifetime of daily insulin shots. Over time, patients with the disease can go on to suffer from a range of complications including blindness, heart disease, kidney problems and nerve damage.
Dr. Bernard Zinman, the director of the Leadership Sinai Centre for Diabetes and lead researcher of the study, explained how the new treatment works to CTV News. According to Zinman, by giving type 2 diabetics concentrated levels of insulin for a month early on in their disease, their pancreas, in effect, gets a "a break."
Celiac disease awareness events and gluten-free fairs across the country. Meet gluten-free families and friends, and try new products from your favorite companies. Special Virtual Event!
State of the Union: A Live Chat with Experts on Gluten-Related Disorders
May 3, 2012 at 2 p.m.
Featuring: Alice Bast, Founder and President, National Foundation for Celiac Awareness Alessio Fasano, MD, Director, Center for Celiac Research, University of Maryland Stefano Guandalini, MD, Founder and Medical Director, The University of Chicago Celiac Disease Center Cynthia Kupper, RD, CD, Executive Director of the Gluten Intolerance Group of North America
......."Kaiser's medical staff expressed frustration with plaintiff Jimmy Steen for not treating his diabetes over the last two years, allowing the disease to deteriorate his health and cause permanent damage," he says. "The Kaiser medical staff was shocked to learn that plaintiff Jimmy Steen's prior primary care physician, defendant Dr. Brett Harris Wolff, had never informed plaintiff Jimmy Steen that he suffered from diabetes nor provided plaintiff Jimmy Steen any guidance, instruction, counseling or medication to address the symptoms and effects of his diabetes, or to prevent the permanent damage to his body that would inevitably arise with untreated diabetes.......
Sustained Effects of a Mindfulness-Based Stress-Reduction Intervention in Type 2 Diabetic Patients Design and first results of a randomized controlled trial (the Heidelberger Diabetes and Stress-Study) Mechthild Hartmann, MSC1⇓, Stefan Kopf, MD2, Claudia Kircher, MD2, Verena Faude-Lang, MD1,3, Zdenka Djuric, MD2, Florian Augstein2, Hans-Christoph Friederich, MD1, Meinhard Kieser, PHD4, Angelika Bierhaus, PHD2, Per M. Humpert, MD2, Wolfgang Herzog, MD1 and Peter P. Nawroth, MD2 + Author Affiliations
1Department of Medicine II and Psychosomatics, University of Heidelberg, Heidelberg, Germany 2Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany 3Department of Psychosomatic Medicine and Psychotherapy, University of Hamburg-Eppendorf, Hamburg, Germany 4Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany Corresponding author: Mechthild Hartmann, firstname.lastname@example.org. M.H., S.K., and C.K. contributed equally to this study.
OBJECTIVE To determine whether a mindfulness-based stress reduction (MBSR) intervention is effective for reducing psychosocial distress (i.e., depression, psychosocial stress) and the progression of nephropathy (i.e., albuminuria) and for improving the subjective health status of patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS Patients with type 2 diabetes and microalbuminuria were randomized to a mindfulness-based intervention (n = 53) or a treatment-as-usual control (n = 57) group. The study is designed to investigate long-term outcomes over a period of 5 years. We present data up to the first year of follow-up (FU).
RESULTS At FU, the MBSR group showed lower levels of depression (d = 0.71) and improved health status (d = 0.54) compared with the control group. No significant differences in albuminuria were found. Per-protocol analysis also showed higher stress reduction in the intervention group (d = 0.64).
CONCLUSIONS MBSR intervention achieved a prolonged reduction in psychosocial distress. The effects on albuminuria will be followed up further.
It's not the image nor the label one often associates with dedicated doctors. But on Sunday afternoon, "Rockin' Docs" will be rockin' out at the Electric Factory, complete with special effects and pretty impressive music sets offered by five bands.
A major breakthrough in the quest for oral insulin was announced by Dr. Daniel DeBrouse, CEO, CSO of Tamarisk Technologies of Meeker, OK. This comes just days after his publishing of nearly a decade of research in oral drug delivery.
A Devon man who received his first jab of insulin as a three-year-old boy in 1935 has joined an elite group of long-suffering diabetes survivors. John Hegan began the then relatively new treatment for...
DiabetesMine is proud to announce a new program this year in our continued efforts to “push the envelope” on diabetes innovation. We’re asking YOU, the empowered PWDs (people with diabetes) to tell us about your most pressing design needs.
An very special presentation took place at the Riverside in Towcester when Susan Parker who has been an insulin dependent diabetic for 60 years was presented with the Lawrence Medal by Dr Charles Fox and Dr Anne Kilvert.
May is Celiac Awareness Month. For my part, I'm GIVING AWAY electronic copies of my new cookbooklet, So What CAN You Eat? Gluten-Free Paleo Vegan (mostly) Recipes for Health and Weight Loss . (It'll...
In a move that could help the government trim its burgeoning health care costs, the Food and Drug Administration may soon permit Americans to obtain some drugs used to treat conditions such as high blood pressure and diabetes without obtaining a...
NEW ORLEANS, LA -- (Marketwire) -- 04/27/12 -- Aaron Neville of the Neville Brothers first sold his music in Peaches Records Store. Countless other local musicians have gotten their start selling their tunes here. Now the record store is showcasing a promising new talent, New Orleans-based teen sensation Rici Jo, hosting her CD launch parties here on April 28 and May 5. What makes 16 year old Rici Jo's story a little different from most other musicians' is that while she hails from the town of sugary beignets, she has type 1 diabetes, so she needs a steady stream of insulin in order to keep singing out strong.
NEW YORK (Reuters Health) - Small financial incentives aimed at getting physicians to make sure their diabetic patients receive recommended routine exams may not lead to changes in doctors' behavior, according to a new study from Canada.